This systematic review and meta-analysis compared weight loss and other health markers for people with obesity. Researchers analyzed data from 3,545 individuals who received either cagrisema or cagrilintide alone, or semaglutide. The goal was to see which treatment led to the most weight loss and how it affected blood sugar and cholesterol levels.
The study found that cagrisema monotherapy resulted in significantly greater weight loss compared to semaglutide. The average difference was about 7.5 percent in body weight change. Cagrilintide alone showed weight loss results comparable to semaglutide. Other measures like fasting glucose and HbA1c also improved across the treatments.
Safety profiles were generally similar between cagrisema and semaglutide for overall and serious adverse events. However, combination therapy with cagrisema and semaglutide led to more issues at the injection site and higher rates of nausea. Cagrilintide monotherapy carried a higher risk of serious adverse events compared to semaglutide. Readers should note that this is a meta-analysis of existing trials, which provides a broad view but relies on the data provided in those original studies.